nouscom logo.png
Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round
14 nov. 2023 01h00 HE | Nouscom Srl
New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key...
logo.jpg
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
13 juin 2022 01h00 HE | ImCheck Therapeutics SAS
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...